4SC reports Phase I data for resminostat in pancreatic and biliary tract cancer

In September, 4SC AG (Xetra:VSC) said partner Yakult Honsha Co. Ltd. (Tokyo:2267) reported data from a Phase I trial in 27 patients with advanced pancreatic or biliary tract cancer showing that resminostat (4SC-201) plus Teysuno tegafur/gimeracil/oteracil potassium led to a median overall survival (OS) of 10.2 months, with no disease progression for a median of 5.5 months. The open-label, Japanese trial's primary endpoint evaluates dose-limiting toxicities (DLTs). Secondary endpoints include safety, OS and time to disease progression. Data were presented at the European Society for Medical Oncology meeting in Madrid.

4SC said Yakult Honsha plans to start a Phase II trial "in the near future" to evaluate the combination in second-line biliary tract cancer. 4SC is evaluating resminostat as a single agent in the Phase II RESMAIN trial in patients with advanced cutaneous T cell lymphoma (CTCL)...